We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Hims & Hers Health, Inc. (HIMS - Free Report) . Shares have lost about 7.7% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Hims & Hers Health due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Hims & Hers Health, Inc. before we dive into how investors and analysts have reacted as of late.
Hims & Hers’ Q2 Earnings Miss, Gross Margin Down
Hims & Hers Health reported quarterly adjusted loss per share of 10 cents in second-quarter 2026, against the year-ago period’s adjusted earnings per share of 17 cents. The metric was wider than the Zacks Consensus Estimate of loss per share of 7 cents.
GAAP loss per share for the quarter was 37 cents against the year-ago period’s EPS of 17 cents.
HIMS’ Revenues in Detail
Hims & Hers registered revenues of $753.2 million in the second quarter, up 38.2% year over year. The figure surpassed the Zacks Consensus Estimate by 9.1%.
Solid revenues from both geographic segments drove the top line.
Hims & Hers’ Geographical Results
In the second quarter of 2026, revenues in the United States increased 15.7% year over year to $621.8 million.
Rest of the World revenues grossed $131.4 million, up from the year-ago quarter’s $7.5 million.
During the reported quarter, subscribers were 2.9 million, up 18.5% year over year.
Monthly online revenue per average subscriber increased 21.1% year over year to $92 in the second quarter. Per management, the uptick was primarily driven by changes in product mix, including uptake of HIMS’ weight loss offerings.
HIMS’ Margin Analysis
In the second quarter of 2026, Hims & Hers’ gross profit increased 15.5% year over year to $480.8 million. However, the gross margin contracted 1256 basis points to 63.8%.
Marketing expenses increased 20.4% year over year to $262.2 million, while technology and development expenses jumped 45.1% year over year to $54.9 million. General and administrative expenses surged 145.8% year over year to $165.4 million, while operations and support expenses increased 43.6% year over year to $95.5 million. Operating expenses of $577.9 million increased 48.4% year over year.
Operating loss totaled $97.2 million against the year-ago quarter’s operating profit of $26.7 million.
Hims & Hers’ Financial Position
Hims & Hers exited second-quarter 2026 with cash and cash equivalents and short-term investments of $841 million compared with $750.9 million at the end of first-quarter 2026.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $53.4 million compared with $89.9 million a year ago.
HIMS’ Outlook
Hims & Hers has provided its revenue outlook for the third quarter and raised the same for 2026.
The company projects revenues for the third quarter of 2026 in the range of $880 million to $900 million, reflecting an uptick of 47%-50% year over year.
For the full year, HIMS now projects revenues in the range of $3.1 billion to $3.3 billion (representing growth of 32%-41% from 2025 levels), up from the prior outlook of $2.8 billion to $3 billion (representing growth of 19%-28% from 2025 levels).
How Have Estimates Been Moving Since Then?
Since the earnings release, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted -27.35% due to these changes.
VGM Scores
At this time, Hims & Hers Health has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Hims & Hers Health has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Hims & Hers Health is part of the Zacks Medical Info Systems industry. Over the past month, 10x Genomics (TXG - Free Report) , a stock from the same industry, has gained 12.2%. The company reported its results for the quarter ended June 2026 more than a month ago.
10x Genomics reported revenues of $151.04 million in the last reported quarter, representing a year-over-year change of -12.6%. EPS of -$0.14 for the same period compares with $0.28 a year ago.
10x Genomics is expected to post a loss of $0.27 per share for the current quarter, representing a year-over-year change of -22.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -2%.
10x Genomics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report?
A month has gone by since the last earnings report for Hims & Hers Health, Inc. (HIMS - Free Report) . Shares have lost about 7.7% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Hims & Hers Health due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Hims & Hers Health, Inc. before we dive into how investors and analysts have reacted as of late.
Hims & Hers’ Q2 Earnings Miss, Gross Margin Down
Hims & Hers Health reported quarterly adjusted loss per share of 10 cents in second-quarter 2026, against the year-ago period’s adjusted earnings per share of 17 cents. The metric was wider than the Zacks Consensus Estimate of loss per share of 7 cents.
GAAP loss per share for the quarter was 37 cents against the year-ago period’s EPS of 17 cents.
HIMS’ Revenues in Detail
Hims & Hers registered revenues of $753.2 million in the second quarter, up 38.2% year over year. The figure surpassed the Zacks Consensus Estimate by 9.1%.
Solid revenues from both geographic segments drove the top line.
Hims & Hers’ Geographical Results
In the second quarter of 2026, revenues in the United States increased 15.7% year over year to $621.8 million.
Rest of the World revenues grossed $131.4 million, up from the year-ago quarter’s $7.5 million.
During the reported quarter, subscribers were 2.9 million, up 18.5% year over year.
Monthly online revenue per average subscriber increased 21.1% year over year to $92 in the second quarter. Per management, the uptick was primarily driven by changes in product mix, including uptake of HIMS’ weight loss offerings.
HIMS’ Margin Analysis
In the second quarter of 2026, Hims & Hers’ gross profit increased 15.5% year over year to $480.8 million. However, the gross margin contracted 1256 basis points to 63.8%.
Marketing expenses increased 20.4% year over year to $262.2 million, while technology and development expenses jumped 45.1% year over year to $54.9 million. General and administrative expenses surged 145.8% year over year to $165.4 million, while operations and support expenses increased 43.6% year over year to $95.5 million. Operating expenses of $577.9 million increased 48.4% year over year.
Operating loss totaled $97.2 million against the year-ago quarter’s operating profit of $26.7 million.
Hims & Hers’ Financial Position
Hims & Hers exited second-quarter 2026 with cash and cash equivalents and short-term investments of $841 million compared with $750.9 million at the end of first-quarter 2026.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $53.4 million compared with $89.9 million a year ago.
HIMS’ Outlook
Hims & Hers has provided its revenue outlook for the third quarter and raised the same for 2026.
The company projects revenues for the third quarter of 2026 in the range of $880 million to $900 million, reflecting an uptick of 47%-50% year over year.
For the full year, HIMS now projects revenues in the range of $3.1 billion to $3.3 billion (representing growth of 32%-41% from 2025 levels), up from the prior outlook of $2.8 billion to $3 billion (representing growth of 19%-28% from 2025 levels).
How Have Estimates Been Moving Since Then?
Since the earnings release, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted -27.35% due to these changes.
VGM Scores
At this time, Hims & Hers Health has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Hims & Hers Health has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Hims & Hers Health is part of the Zacks Medical Info Systems industry. Over the past month, 10x Genomics (TXG - Free Report) , a stock from the same industry, has gained 12.2%. The company reported its results for the quarter ended June 2026 more than a month ago.
10x Genomics reported revenues of $151.04 million in the last reported quarter, representing a year-over-year change of -12.6%. EPS of -$0.14 for the same period compares with $0.28 a year ago.
10x Genomics is expected to post a loss of $0.27 per share for the current quarter, representing a year-over-year change of -22.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -2%.
10x Genomics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.